ABUSHealthcare · BiotechnologyABUS Stock Forecast: Arbutus Biopharma Corp. Price Predictions for 2026-2027
The 1 Wall Street analysts covering Arbutus Biopharma Corp. hold a median 12-month price target of $5.54 — +19.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 99 of 100 as at 8 Aug 2026 — among the strongest tenth. Here, the model and the Street point the same way.
ABUS stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Arbutus Biopharma Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (99): Sales and profits are climbing, and climbing faster than before.
Accruals (19): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
The rank is the raw material. Whether the rules would actually own Arbutus Biopharma Corp. — and when they’d sell — is the membership.
ABUS stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on ABUS, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +19.7% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 14 Nov 2025 | Chardan Capital | Maintains | Buy | $5.00 |
| 11 Aug 2025 | Chardan Capital | Maintains | Buy | — |
| 28 Mar 2025 | Chardan Capital | Maintains | Buy | — |
| 21 Jan 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 20 Nov 2024 | Chardan Capital | Maintains | Buy | — |
| 18 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 7 Nov 2024 | Chardan Capital | Maintains | Buy | — |
| 7 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 6 Nov 2024 | Chardan Capital | Maintains | Buy | $4.00 → $4.50 |
| 5 Sept 2024 | Jefferies | Maintains | Buy | — |
| 2 Aug 2024 | JMP Securities | Maintains | Market Outperform | — |
| 7 June 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 6 June 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 5 June 2024 | Chardan Capital | Maintains | Buy | — |
| 3 May 2024 | Chardan Capital | Reiterates | Buy | — |
| 4 Apr 2024 | JMP Securities | Reiterates | Market Outperform | — |
| 1 Mar 2024 | Chardan Capital | Reiterates | Buy | — |
| 1 Mar 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 12 Sept 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 4 Aug 2023 | Chardan Capital | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
ABUS analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Arbutus Biopharma Corp. (ABUS) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 5.6×
- Price / sales
- 4.8×
- Price / book
- 3.5×
- EV / EBITDA
- 5.3×
Cheaper than 66% of US stocks
Cheaper than 27% of US stocks
Cheaper than 31% of US stocks
Cheaper than 53% of US stocks
- Revenue growth (YoY)
- 10054.5%
- Earnings growth (YoY)
- 10054.5%
- Gross margin
- —
- Operating margin
- 94.4%
- Net margin
- 84.0%
Higher than 99% of US stocks
Higher than 99% of US stocks
Higher than 99% of US stocks
Higher than 99% of US stocks
- Return on equity
- 94.7%
- Return on assets
- 49.2%
- Dividend yield
- —
Higher than 96% of US stocks
Higher than 99% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
ABUS vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ABUS appears on the weeks it earns a place.
Frequently asked questions about ABUS stock
What is the ABUS stock price forecast for 2026-2027?
The 1 Wall Street analysts covering Arbutus Biopharma Corp. have a median 12-month price target of $5.54, with estimates ranging from $5.54 to $5.54. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is ABUS stock a buy right now?
Of the 1 analysts covering Arbutus Biopharma Corp., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Arbutus Biopharma Corp. 99 out of 100 across roughly 4,600 US stocks as at 8 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank ABUS?
As at 8 Aug 2026, Arbutus Biopharma Corp. ranks 99 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (99 of 100).
Will ABUS stock go up?
No one can know that. What the data says: the median 12-month target from 1 analysts implies +19.7% from the last close, and Ticker Nerd's factor model ranks Arbutus Biopharma Corp. 99 out of 100 as at 8 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the ABUS stock forecast for 2030?
No analyst covering Arbutus Biopharma Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ABUS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5.54 to $5.54 over the next 12 months.
How has ABUS stock performed over the past year?
Arbutus Biopharma Corp. returned +36.2% over the 12 months to 7 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Arbutus Biopharma Corp. do?
Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company specializing in virology with a focus on developing novel therapeutics for infectious diseases, particularly chronic hepatitis B virus (cHBV). The company leverages its deep expertise in virology to create innovative treatments that target HBV through multiple mechanisms of action, aiming to provide functional cures for patients with unmet medical needs.
About Arbutus Biopharma Corp.
Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company specializing in virology with a focus on developing novel therapeutics for infectious diseases, particularly chronic hepatitis B virus (cHBV). The company leverages its deep expertise in virology to create innovative treatments that target HBV through multiple mechanisms of action, aiming to provide functional cures for patients with unmet medical needs. Its proprietary pipeline features imdusiran (AB-729), a subcutaneously delivered RNAi therapeutic that suppresses all HBV antigens including HBsAg, currently in phase 2a clinical trials, and AB-101, an oral PD-L1 inhibitor in phase 1a/1b trials designed to reawaken HBV-specific immune responses. Arbutus Biopharma Corporation also advances its in-house Lipid Nanoparticle (LNP) delivery technology to enhance therapeutic delivery. These efforts position the company as a key player in the biotechnology sector, contributing to improved treatment options in hepatology and viral disease management. Founded in 2005 and headquartered in Warminster, Pennsylvania, Arbutus Biopharma Corporation maintains a portfolio of clinical and pre-clinical assets dedicated to addressing critical virology challenges.
CEO Ms. Lindsay Androski J.D., M.B.A. · 19 employees · United States · https://www.arbutusbio.com